Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

244.11 +1.06 (+0.44%)

Official Closing Price Updated: 4:04 PM EDT, Jul 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

1 Cash-Producing Stock with Exciting Potential and 2 We Avoid

August 15, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Topics Economy

Fed Rate Cut Hopes Fuel Market Rally: Inflation Data Steers September Expectations

August 14, 2025

Optimism has surged through financial markets as recent economic data, particularly the July Consumer Price Index (CPI), has significantly bolstered expectations for a 25-basis-point interest rate cut...

Via MarketMinute

Topics Bonds Credit Cards Economy

These S&P500 stocks are moving in today's session ↗

August 14, 2025

Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today ↗

August 03, 2025

Via The Motley Fool

Expert Outlook: AbbVie Through The Eyes Of 4 Analysts ↗

August 01, 2025

Via Benzinga

Inflation Report Sparks Global Rally: How Tame CPI is Reshaping Market Expectations

August 13, 2025

A surprisingly subdued July Consumer Price Index (CPI) report has sent ripples of optimism across global financial markets, igniting a worldwide rally and significantly recalibrating expectations for...

Via MarketMinute

Topics Bonds Credit Cards Economy

ABBV Q2 Deep Dive: Immunology and Neuroscience Growth Outpace Aesthetics, Guidance Trimmed

August 13, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share...

Via StockStory

My 3 Favorite Stocks to Buy Right Now ↗

August 10, 2025

These tried-and-true businesses are performing well against a volatile backdrop.

Via The Motley Fool

Topics Intellectual Property

4 of My Favorite Dividend Stocks for the Next 5 Years ↗

August 09, 2025

All four pay safe, reliable, and growing dividends.

Via The Motley Fool

3 Stocks Retirees Should Absolutely Love ↗

August 09, 2025

These stocks check off all the boxes for investors no longer receiving a paycheck.

Via The Motley Fool

Topics Economy Retirement

Is the Vanguard Value ETF the Simplest Way to Consistently Collect More Passive Income Than the S&P 500? ↗

August 09, 2025

This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends.

Via The Motley Fool

Topics ETFs Regulatory Compliance Stocks

Federal Reserve Poised for Rate Cuts as Economic Headwinds Mount, Tariffs Complicate Outlook

August 08, 2025

Financial markets are currently pricing in a high likelihood of the Federal Reserve initiating interest rate cuts before the year-end, a significant shift in monetary policy that reflects growing...

Via MarketMinute

Topics Bankruptcy Economy Government

3 Market-Beating Stocks with Solid Fundamentals

August 08, 2025

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

Via StockStory

AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules ↗

August 08, 2025

The federal court dismissed a lawsuit from business chambers over the Medicare drug price negotiation program.

Via Benzinga

Topics Lawsuit

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% ↗

August 08, 2025

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat.

Via Benzinga

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country' ↗

August 06, 2025

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Via Benzinga

Topics Government World Trade

1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off

August 05, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

AbbVie (ABBV) Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

AbbVie Raises 2025 Outlook After Q2 Beat ↗

August 04, 2025

Via The Motley Fool

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics ↗

August 03, 2025

Via Benzinga

Topics Economy Government

3 Unstoppable Stocks to Buy in August ↗

August 02, 2025

Here are hot stocks to buy in a hot month.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Champion Stocks I'm Watching in 2025 ↗

August 02, 2025

Other investors might want to watch these high-yield dividend stocks, too.

Via The Motley Fool

Topics Earnings Government World Trade

Why AbbVie Stock Flew Higher on Friday ↗

August 01, 2025

A solid quarterly earnings report reverberated though the pundit community that day.

Via The Motley Fool

Discover which S&P500 stocks are making waves on Friday. ↗

August 01, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.

Via Chartmill

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion ↗

August 01, 2025

AbbVie raised full-year guidance after Q2 sales beat expectations, with analysts lifting price targets despite an earnings miss.

Via Benzinga

Topics Earnings

Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining ↗

August 01, 2025

Big-name bidders, strategic reviews, and PE exits define an active, high-stakes M&A market so far this summer.

Via Benzinga

5 Dividend Stocks With Solid Returns And More Growth Ahead ↗

August 01, 2025

Via Benzinga

Why AbbVie (ABBV) Stock Is Up Today

August 01, 2025

Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.7% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year...

Via StockStory

3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double ↗

August 01, 2025

These pharmaceutical giants are well worth a second look.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.